Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders

Conditions:   Accelerated Phase of Disease;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Myelomonocytic Leukemia;   Chronic Phase of Disease;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Recurrent DiseaseInterventions:   Drug: Tipifarnib;   Other: Laboratory Biomarker AnalysisSponsor:   National Cancer Institute (NCI)Active, not recruiting - verified February 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials